buyWeak cluster of 2
Matsuda Masaru bought $19k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 5,657 shares at an average of $3.28, traded May 31, 2024, filed Dec 3, 2024.
Conviction score
23Value
$19k
5,657 shares
Holdings after
187,030
+3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001787306-24-000168, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 31, 2024 | POpen-market purchase Common Stock | +4,000 | $1.69 | $6,768 | 185,373 | Dec 3, 2024 |
| Nov 30, 2024 | POpen-market purchase Common Stock | +1,657 | $7.11 | $12k | 187,030 | Dec 3, 2024 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 3Weak | sell 210b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick See Remarks | $24k | 1,691 | |
| 16Weak | sell 210b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Watanabe Todd Franklin See Remarks | $228k | 15,000 | |
| 18Weak | buy 2 | ARQT Arcutis Biotherapeutics, Inc. | Watanabe Todd Franklin See Remarks | $21k | 6,038 | |
| 21Weak | sell 310b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Welgus Howard G. director | $125k | 10,000 | |
| 10Weak | buy | ARQT Arcutis Biotherapeutics, Inc. | Edwards Larry Todd See Remarks | $7,767 | 1,093 | |
| 31Weak | sell 4 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick See Remarks | $163k | 16,023 | |
| 10Weak | sell 410b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Matsuda Masaru See Remarks | $17k | 1,775 | |
| 46Moderate | sell 5 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick See Remarks | $713k | 69,226 | |
| 50Moderate | sell 5 | ARQT Arcutis Biotherapeutics, Inc. | Curran Terrie director | $94k | 8,687 | |
| 21Weak | sell 510b5-1 | ARQT Arcutis Biotherapeutics, Inc. | Burnett Patrick See Remarks | $134k | 15,441 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.